X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CT7001 (samuraciclib) is an investigational oral and first-in-class inhibitor of CDK7, in combination with ARV-471 (vepdegestrant), an investigational oral PROTAC degrader is being evaluated for the treatment of ER+, HER2- metastatic breast cancer.
Lead Product(s): Samuraciclib,Vepdegestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Samuraciclib (CT7001) - an oral CDK7 inhibitor in combination with Fulvestrant is being evaluated in phase 2 clinical trials for the treatment of HER2- advanced breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
CT7001 (samuraciclib) is an oral and first-in-class inhibitor of CDK7, and the Menarini Group's (Menarini) oral selective estrogen receptor degrader (SERD), elacestrant, in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer.
Lead Product(s): Samuraciclib,Elacestrant Dihydrochloride
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K, which is the obligate co-factor for CDK12/13, giving both first-in-class and best-in-class potential treatment of advanced solid tumors, including breast, ovarian and Ewing's Sarcoma.
Lead Product(s): CT7439
Therapeutic Area: Oncology Product Name: CT7439
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
The collaboration aims to evaluate the novel combination of CT7001 (samuraciclib), an oral, first-in-class inhibitor of CDK7, and Arvinas’ ARV-471 (vepdegestrant), an investigational oral PROTAC® estrogen receptor protein degrader being developed in metastatic breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arvinas
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2023
Details:
The Company intends to use the proceeds to fund ongoing and planned CT7001 (samuraciclib) clinical trials, ongoing development of its CDK12/13 inhibitor / Cyclin-K glue-degrader, and for working capital and general corporate purposes.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing December 01, 2022
Details:
CT7001 (samuraciclib), an oral CDK7 inhibitor, is a promising therapeutic strategy in cancer, as CDK7 regulates transcription of cancer-causing genes and promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 01, 2022
Details:
Under the terms of the agreement, Pfizer will provide global development capabilities and expertise to support Carrick’s Phase 2 study of CT-7001 (samuraciclib) in combination with fulvestrant for CDK4/6i-resistant HR+, HER2- advanced breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 01, 2022
Details:
Clinical data on samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, regulates the transcription of cancer-causing genes,support its continued development in breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
Samuraciclib inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
